

Transcranial Blood–Brain Barrier Opening in Alzheimer’s Disease Patients Using A Portable Focused Ultrasound System with Real-Time 2-D Cavitation Mapping

Sua Bae^{1†}, Keyu Liu^{1†}, Antonios N. Poulipoulos^{1†}, Robin Ji¹, Sergio Jiménez-Gambín¹, Omid Yousefian¹, Alina R. Kline-Schoder¹, Alec J. Batts¹, Danae Kokossis², Akiva Mintz³, Lawrence S. Honig⁴, and Elisa E. Konofagou^{1,3*}

[†]These authors contributed equally to this work.

Abstract

Background: Focused ultrasound (FUS) in combination with microbubbles has recently shown great promise in facilitating blood-brain barrier (BBB) opening for drug delivery and immunotherapy in Alzheimer’s disease (AD). However, it is currently limited to systems integrated within the MRI suites or requiring post-surgical implants, thus restricting its widespread clinical adoption. In this pilot study, we investigate the clinical safety and feasibility of a portable, non-invasive neuronavigated FUS system with integrated real-time 2D microbubble cavitation mapping.

Methods: A phase 1 clinical study with mild to moderate AD patients (N=6) underwent a single session of microbubble-mediated FUS to induce transient BBB opening (BBBO). Microbubble activity under FUS was monitored with real-time 2-D cavitation maps and dosing to ensure the efficacy and safety of the FUS treatment. Post-operative MRI was used for BBB opening and closure confirmation as well as safety assessment. Changes in AD biomarker levels in both blood serum and extracellular vesicles (EVs) were evaluated, while changes in amyloid-beta (Aβ) load in the brain were assessed through ¹⁸F-Florbetapir PET.

Results: BBBO was achieved in 5 out of 6 subjects with an average volume of 983±626 mm³ following FUS at the right frontal lobe both in white and gray matter regions. The outpatient treatment was completed within 34.8±10.7 min. Cavitation dose significantly correlated with the BBBO volume ($R^2>0.9$, N=4), demonstrating the portable FUS system’s capability of predicting opening volumes. The cavitation maps co-localized closely with the BBBO location, representing the first report of real-time transcranial 2-D cavitation mapping in the human brain. Larger opening volumes correlated with increased levels of AD biomarkers, including Aβ (p=0.0014) and Aβ40 (p=0.074), Tau (p=0.014), and Phospho-Tau (p=0.0015), and FUS (p=0.0008), as well as increased derived EVs

sampled 3 days after FUS ($N=5$). From PET scans, subjects showed a lower $A\beta$ load increase in the treated frontal lobe region compared to the contralateral region. Reduction in asymmetry standardized uptake value ratios (SUVR) correlated with the harmonic cavitation dose ($R^2>0.9$, $N=3$). Clinical changes in the mini-mental state examination over 6 months were within the expected range of cognitive decline with no additional changes observed as a result of FUS.

Conclusion: Safety and feasibility of this cost-efficient and portable FUS for BBBO in AD patients were demonstrated with real-time mapping correlating with BBBO volume and a reduction in pathology, as well as serum detection of the AD proteins, $A\beta$ and tau. Our study suggest the potential for accessible FUS treatment in AD, with or without drug delivery.

Keywords: Alzheimer’s disease; blood–brain barrier; focused ultrasound; microbubbles; cavitation mapping;

Author affiliations:

¹Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA

²Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA

³Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA

⁴Department of Neurology and Taub Institute, Columbia University Irving Medical Center 10032, New York, NY, USA

Correspondence to: Sua Bae, Elisa E. Konofagou

Full address: 630 West 168th Street, New York, NY 10032, USA

E-mail: sb4495@columbia.edu, ek2191@columbia.edu

Main Text

Introduction

Alzheimer's disease (AD) is the most common neurodegenerative disorder, typically with progressive amnesic cognitive impairment, and its prevalence increases with the aged population growth [1]. Until recently, there were no effective disease modifying treatments. Recently monoclonal antibodies against amyloid-beta ($A\beta$) have been shown to be effective, including aducanumab [2], lecanemab [3], and donenemab [4]. However, in general, drug treatments may be limited by the blood–brain barrier (BBB) that inhibits the access of therapeutic molecules to the central nervous system [5,6]. Most small molecule drugs, including anti- $A\beta$ monoclonal antibodies, have very limited ability to penetrate the BBB [7–9]. Although direct intracerebral infusion could possibly circumvent the BBB restriction, this invasive procedure entails risks [10].

Microbubble-mediated focused ultrasound (FUS) is a promising non-invasive therapy for enhancing BBB permeability [11]. In this treatment, microbubbles are systemically administered while FUS induces the rapid oscillation of microbubbles, called cavitation, at a targeted volume in the brain (Figure 1). Precise FUS treatment can induce local and transient BBB opening (BBBO) and promote immune response [12,13]. Numerous preclinical studies have proven that BBBO can lead to a decrease in $A\beta$ or tau proteins in the brain and the cognitive improvement with and without drugs by increased immune response such as microglial phagocytosis [14–16].

Many clinical trials have demonstrated that magnetic resonance (MR)-guided focused ultrasound (MRgFUS) can safely and transiently open BBB in patients with Alzheimer's disease [17–20], amyotrophic lateral sclerosis [21], Parkinson's disease [22], glioma [23,24], and brain metastases[25]. Previous studies with Alzheimer's disease patients have shown the modest reduction in ^{18}F -Florbetaben uptake ratio in PET and no cognitive worsening after multiple sessions of MRgFUS treatment [17–20,26]. A recent study reported a substantial reduction in $A\beta$ levels measured by PET in three patients following 6-month MRgFUS combined with aducanumab infusion [27]. While MRgFUS is the most widely used approach for clinical trials of BBBO, it generally requires the patient to stay still with their heads fixed by a stereotaxic frame in the MR scanner for a few hours. Alternatively, an implantable FUS device has been utilized in clinical trials, demonstrating a non-significant reduction in amyloid based on ^{18}F -Florbetafir PET scans after multiple treatments [28]. Although this approach has been proven well-tolerated, it requires a burr hole achieved with brain surgery, making it invasive.

Given the need for repetitive treatments and the advanced age of Alzheimer's disease patients, there is a compelling demand for facilitating a low-cost and non-invasive treatment approach. Portable neuronavigation-guided FUS (NgFUS) systems can provide FUS treatment outside an MR scanner in an outpatient room. Portable systems have been employed in both preclinical and clinical studies [29–32], but only one clinical study has been reported in the context of Alzheimer's disease, showing modest cognitive improvement after FUS [29]. However, this study did not induce BBBO or investigate if there were any changes in amyloid or tau protein load.

In this Phase 1 clinical study (NCT04118764), we assessed the clinical feasibility and safety of BBBO in six subjects with mild-to-moderate Alzheimer's disease using a portable FUS system that we developed and verified in preclinical studies [33–35]. A single 2-minute FUS sonication session was performed per subject without a stereotaxic frame or a MR scanner. Real-time cavitation monitoring was employed to measure the treatment dose and assess its capability of predicting BBBO volume in the human brain. To our knowledge, this is the first report of real-time cavitation mapping in the human brain using a portable FUS system. Neurological and biological effects of the portable FUS system were evaluated by blood biomarker analysis, ¹⁸F-Florbetapir PET scans, and mini-mental state examination (MMSE).

Results

Study Overview

The primary objective of the study is to assess the safety and feasibility of FUS-induced BBBO in Alzheimer's disease patients, using a portable, noninvasive FUS system. Secondary objectives includes testing the feasibility of cavitation mapping and observing changes in ¹⁸F-Florbetapir PET and in blood biomarkers. Six Alzheimer's disease patients (2M/4F, age = 69.7±7.2 yr) were enrolled in a phase 1 trial under FDA and Columbia University IRB approval (NCT04118764) (Table 1). Inclusion and exclusion criteria, including diagnosis of Alzheimer's disease, amyloid positivity on ¹⁸F-Florbetapir PET scan, and an MMSE score between 12 and 26, are listed in Table S1. Figure 2 presents the timeline of the clinical trial. All subjects underwent one session of FUS sonication and had pre- and post-treatment scans, blood tests, and MMSE assessments.

Portable NgFUS system allowed for efficient BBBO

All subjects received a single FUS treatment at the right frontal lobe, while seated in a medical recliner chair in an outpatient unit with the portable NgFUS system guided by neuronavigation and cavitation monitoring (Figure 3). FUS was deployed through a contact area with a diameter of less than 50 mm, which allowed for partial hair shaving instead of complete head shaving (Figure S1). The FUS transmit power was adjusted to achieve a target peak-negative pressure of 0.2 MPa at the focus in the brain, based on the skull-induced attenuation estimates (Table 2). All sessions were uneventful and the average treatment procedure time was 34.8 ± 10.7 min.

Five subjects underwent successful BBBO at the treated location in the frontal lobe as evidenced by post-FUS T1-weighted MRI (Figure 4A), and the quantified contrast-enhanced volume, which serves as a measure of BBBO volume, was 983 ± 626 mm³ (Figure 4C and 4D and Table 2). One participant (subject 3) had no detectable opening, likely due to inadequate microbubble administration and syringe malfunction. Subject 1 exhibited the largest opening volume of 2,013 mm³, which extended to the left thalamus beyond the lateral ventricles while subject 4 exhibited the smallest opening volume of 278 mm³. All of the openings from the 5 subjects were closed within 72 h, which was confirmed by the follow-up scans on day 3 (Figure 4B).

Safety evaluation

There were no serious adverse events (SAEs) and no clinical changes after the treatments. One subject (subject 1) had an adverse event (AE) including both mild skin erythema on day 0 (resolved within 3 days) and asymptomatic cerebral edema with superficial hemorrhagic component on day 3. MRI images showed an area of T2 fluid-attenuated inversion recovery (FLAIR) hyper-intensity on day 3, most intense at the cortical targeted location but extending deeper (Figure S2), with susceptibility-weighted imaging (SWI) hypo-intensity superficially within the same region (Figure S3). The subject was asymptomatic and the MRI abnormalities were all resolved in follow-up scans on day 15. Other subjects did not show abnormalities in the safety MR scans 3 days after the treatment.

Cavitation dose and map showed promising results for predicting the BBBO

To monitor the safety and efficacy of the treatment, cavitation signal during sonication was observed. A single-element transducer was utilized to obtain cavitation dose (CD) for subjects 1–4, while a multi-element imaging array transducer was employed for subjects 5 and 6 to obtain both CD and 2-D cavitation maps.

Figures 5A–5C show the real-time cavitation dose monitoring results from subjects 1–4. For subjects 1, 2, and 4, ultraharmonic and broadband CD increased after the microbubble injection ($t = 20\text{--}30$ s) and persisted until the end of the sonication ($t = 120$ s), indicating the cavitation activity of the injected microbubbles. On the other hand, for subject 3 which exhibited no detectable opening, the increased CD was not sustained over time, resulting in a low cumulative CD (CCD). Across the four subjects, the higher CCDs were detected with increasing BBBO volume (Figure 5C), resulting in strong positive linear correlations ($R^2 > 0.9$, $p < 0.05$).

Figures 5D and 5E depict the real-time 2-D cavitation mapping and its corresponding BBBO region, respectively, obtained from subjects 5 and 6. The cavitation map that shows the spatial distribution of acoustic energy detected from microbubble activity (Figure 5D) roughly matched with the BBBO location (Figure 5E); both the acoustic energy and BBBO locations were shifted to the left side of the focus in subject 5, and aligned with the focus in subject 6. Compared to subject 5, subject 6 showed approximately 12 dB higher averaged acoustic energy in the map and exhibited a larger opening (278 mm^3 vs. 1262 mm^3). From the pixel-wise correlation analysis between the cavitation map and the BBBO, the area under the curve (AUC) of the receiver operating characteristic (ROC) and precision-recall (PR) curves were $\text{AUC}_{\text{ROC}}=0.8$ and $\text{AUC}_{\text{PR}}=0.7$, respectively, indicating good agreement between the cavitation map and the BBBO volume observed in MRI. To our knowledge, this is the first demonstration of 2-D transcranial passive acoustic mapping in the human brain.

Elevated blood biomarker levels correlated with BBBO size

Both serum and serum-derived extracellular vesicle (EV) levels of biomarkers 3 days after FUS were compared with the baseline levels obtained 1–2 hours prior to NgFUS for subject 2–6. Subject 1's biomarker levels were not obtained due to improper handling of the blood specimen and were excluded from the analysis. Figure 6 shows the correlation between BBBO volume and biomarker levels for S100 β in serum, and A β 42, A β 42/A β 40, GFAP, Tau, and pT181 in EVs. Subjects with larger opening volumes displayed elevated serum levels of S100 calcium-binding protein β (S100 β) ($p < 0.05$), indicating compromised BBB integrity [36] (Figure 6A). Furthermore, we identified several statistically-significant positive linear relationships between the opening size and the serum-derived EV levels of Alzheimer's disease-related proteins, while such relationships were not observed with serum biomarker levels. Notably, glial fibrillary acidic protein (GFAP), Tau, and phosphorylated-Tau 181 (pT181) fold-changes exhibited significant linear correlations ($p < 0.05$) (Figure 6D–6F), while the correlations for A β 42 ($p = 0.062$) and

the A β 42/A β 40 ratio ($p = 0.096$) were not statistically significant (Figure 6B and 6C). There were no significant group-wise changes possibly due to the large variation in BBBO volume (Figure S4).

A modest decrease in asymmetry SUVR correlated with the size of BBBO and cavitation dose

Figure 7 shows the percent changes in standard uptake value ratio (SUVR) or asymmetry SUVR of ^{18}F -Florbetapir compared to the baseline. Subject 3 was excluded due to the absence of BBBO. Although there was no group-wise reduction in SUVR (Figure 7A–7C, Table 3), all subjects with BBBO showed a modest reduction in asymmetry SUVR which assesses the SUVR in the treated region compared to that of the contralateral region (Figure 7D–7F, Table 3). Specifically, asymmetry values decreased by $1.47 \pm 0.77\%$ ($p=0.013$) in the frontal lobe and by $0.90 \pm 0.26\%$ ($p=0.001$) in the hemisphere at the 2nd follow-up compared to the baseline. A non-significant linear relationship ($R^2=0.69$, $p=0.08$) was measured between the BBBO volume and the 1st follow-up asymmetry changes within the respective volumes (Figure 7G). A relationship of the asymmetry SUVR change with CD was analyzed among subjects who exhibited BBBO with cavitation monitoring using a single-element detector (subject 1, 2 and 4). Strong negative linear relationship was observed between the 1st follow-up asymmetry changes and the ultraharmonic CCD ($R^2=0.998$, $p=0.026$) although the number of subjects were small (Figure 7H). Changes in SUVR and asymmetry values for each subject are listed in Table S3 and PET images are presented in Figure S5. SUVR Changes in Centiloid units are shown in Figure S12 to enable standardized comparison with other studies.

A single BBBO treatment did not significantly alter cognitive function

Comparing the baseline scores, the MMSE score decreased by 1.80 ± 2.71 among the five subjects with BBBO and by 2.50 ± 2.93 among all six enrolled subjects, approximately 3 months after NgFUS. When compared with the Alzheimer's disease neuroimaging initiative (ADNI) database, subjects with successful BBBO did not exhibit statistically different changes in MMSE over a similar time frame ($p > 0.45$), indicating no cognitive changes due to FUS-induced BBBO (Table S2). Individual MMSE scores are listed in Table S4.

Targeting accuracy and precision

Targeting of the FUS transducer during treatment was performed using a manual arm. The distance and angular errors of manual transducer positioning were 5.7 ± 1.4 mm and $11.2\pm 2.5^\circ$, respectively. Mean absolute deviation and maximum distance of the subject motion during the 2-min treatment were 0.3 ± 0.1 and 1.2 ± 0.2 mm when using a head and chin rest (subjects 4–6), and 2.3 mm and 9.4 mm without using the rest (subject 3) (Figure S6, Table 2). Distance between the centroid of the BBBO and the simulated focus was 12.3 ± 6.1 mm, mostly along the FUS trajectory.

Discussion

In this pilot study, we demonstrated the feasibility and safety of the portable FUS system with cavitation monitoring for BBB permeability enhancement at the right frontal lobe in six Alzheimer's disease patients. Five out of six subjects underwent localized BBBO which resolved within 72 h. One AE occurred and resolved in 15 days, and no SAE was reported. No clinically significant changes were observed in SUVR or cognitive test scores after FUS; however, the asymmetry SUVR reduced modestly and exhibited a linear correlation with the BBBO volume. The cavitation dose demonstrated correlations with the BBBO volume, blood biomarker level increase, and the asymmetry SUVR decrease, proving the potential benefits of integrated cavitation monitoring to predict treatment outcomes.

In clinical studies using MRgFUS, acoustic cavitation dose maps were generated by sonicating dozens of subspots and mapping the measured cavitation dose to each subspot, assuming that the received cavitation signals originated only from the focus, neglecting off-site cavitation [24,25,37]. In contrast, our portable FUS system can provide a real-time 2D cavitation map, not only offering off-target cavitation imaging for safety monitoring and targeting accuracy but also enabling a more precise cavitation dose estimation localized at the target for better BBB opening prediction. To our knowledge, this is the first time that 2-D cavitation maps have been obtained in the human brain during BBB opening.

Although we aimed to deliver the same acoustic pressure at the brain target, the BBBO size varied among the subjects from 278 mm^3 to 2013 mm^3 . This variability could be attributed to the challenges in estimation of skull-induced attenuation, which determined the FUS transmit power. The attenuation estimates may have been affected by CT-MR registration errors in the acoustic simulation ($5\text{--}10$ mm in distance and $1\text{--}16^\circ$ in angle) that we identified at the conclusion of the trial. Another factor may lie in the transducer positioning errors which caused discrepancies

between the trajectory used for the simulation and the achieved trajectory during treatment (Table 2). The re-estimated pressure map after correcting the errors and the trajectories showed higher acoustic energy for larger opening cases (Figure S7A), with the most intense energy distribution in subject 1. The re-estimated maximum pressure in the brain (Table S5) showed a linear relationship ($R^2 = 0.84$) with the contrast-enhanced volume (Figure 7B), which may explain the variance in BBBO size across the subjects and the AE in subject 1.

Five subjects showed contrast enhancement within an ellipsoidal volume along the FUS beam trajectory (Figure 4C and 4D, and Movie S1) consistent with the cigar-shaped focus (Figure S7A). Although the FUS focal volume included more WM than GM, the opening volume exhibited similar proportions of GM and WM (Figure S8). The higher probability of opening in GM than in WM was reported in our previous non-human primate (NHP) studies [34,38,39], where GM exhibited increased susceptibility to BBBO relative to WM, indicated by increased contrast enhancement on T1-weighted MRI. Additionally, the non-uniformly distributed opening within the focal volume may be explained by the regional difference in vascular density and tissue property, or increased ultrasound attenuation [38,40–43].

In subject 4, the contrast enhancement on MRI was found not only along the FUS trajectory from the superior frontal cortex to the cingulate cortex, but also along the cingulate sulcus in the anterior-posterior direction (indicated with white arrowheads in Figures 4A and 4C, and S9C). The sulcal enhancement beyond the ellipsoidal focus might not indicate BBBO, because it extended approximately 22 mm posterior from the focus while the focal size is only 6 mm wide. Instead, this vessel-like extravasation of the contrast agent might have occurred through the vessel wall or the perivascular space that extends along the perforating vessels [44], indicating a potential increase in permeability of the blood-meningeal barrier. A possible explanation might be that the contrast agent entered the perivascular space through the disrupted BBB within the ellipsoidal focus and then permeated posteriorly along the cingulate sulcus. This finding may be consistent not only with recent preclinical studies on glymphatic clearance effect of microbubble-mediated FUS in rodents [45] but also with clinical studies using MRgFUS [46,47]. These clinical studies also demonstrated blood-meningeal barrier opening and glymphatic clearance in humans, reporting hyperintense linear enhancement along the hippocampal fissure [47] and contrast accumulation in the subarachnoid space at the frontal lobe [46] following BBBO.

The first possible reason for the BBBO failure in subject 3 is the delayed bolus injection of compromised microbubbles due to the malfunction of the syringe/catheter system. The catheter was blocked at the initial injection attempt, resulting in the pressurization inside the syringe and

the destruction of the microbubbles. Although the microbubble solution was eventually injected at $t = 20$ s after the start of sonication, the increases in CDs were minimal compared to other subjects (Figures 5A and 5B). The second reason could be attributed to subject movement. The head and chin rest were not used for this subject, resulting in the medial movement of ~ 9 mm during the 2-min sonication, which was approximately 6–10 times larger than those of other subjects (Figure S6 and Table 2). The subject movement (i.e., movement of the focus) might have compromised the localized acoustic energy delivered, as evidenced by the reduced CDs at $t = 90$ s coinciding with the sudden movement (gray arrows in both Figure 5A and Figure S6A).

In this study, statistically significant relationships between the opening size and harmonic, ultraharmonic, and broadband cavitation energies were detected (Figure 5C), consistent with our preclinical studies with mice and NHPs [34,48,49]. A recent study with MRgFUS in humans also showed the correlation between the subharmonic acoustic emission and the contrast-enhanced T1-weighted MR signal [24]. All subjects with BBBO showed overall increases in CD 20–30 s after the microbubble bolus injection (Figure 5A and 5B), indicating the onset of microbubble cavitation activity in the sonicated region. In some cases, the CD showed a high fluctuation before the major increase (ultraharmonic CD in subject 4 and 6) or did not increase even after the flush (harmonic CD in subject 4). Compared to our preclinical studies with the same FUS transducer [35,50] where flat CD was usually observed before the injection in NHPs fixed by a stereotaxic frame, the baseline CD in this study was relatively unstable potentially due to motion. In addition, fluctuations in CD can also result from tissues, small air-bubbles in the coupling gel, or the membrane on the water cone [51].

The reduction in SUVR was less pronounced in our study than in previous studies using an implantable FUS device [28] or using an MRgFUS system [17–20,27]. This difference can be attributed to the fact that we conducted a single session of treatment, while the prior studies involved 2–7 treatment sessions with larger treatment volumes. Nevertheless, we found significant decreases in the asymmetry at the 2nd follow-up (Figure 7E and 7F), indicating a lower $A\beta$ accumulation rate or elimination of amyloid in the treated side compared to the contralateral side. These asymmetry changes after FUS are consistent with findings reported in prior studies [17–20,26–28]. In addition, this lowered asymmetry SUVR across the treated frontal lobe and the hemisphere demonstrates the potential of FUS to exert holistic therapeutic effects beyond the treated region. When measured within the BBBO volumes in GM and WM (Figure 7D), the asymmetry did not show an apparent group-wise reduction possibly due to the small and variable BBBO volumes across the subjects. However, they correlated with the FUS

treatment characteristics (i.e., BBBO size and CCDs) (Figures 7G and 7H). A larger BBBO or a higher harmonic CCD was related to the reduced A β accumulation in the treated region relative to the contralateral region.

Preclinical studies have reported improved cognitive function after FUS [15,52,53] and a clinical study using MRgFUS has shown a cognitive improvement measured by the caregiver-administered neuropsychiatric inventory (CGA-NPI) [18]. However, the majority of clinical studies so far have reported non-significant changes in cognitive improvement following FUS-induced BBBO, examined by MMSE and ADAS-cog, evidencing no worsening of cognitive decline due to FUS [17,19,20]. Our MMSE results are also consistent with these findings.

A previous MRgFUS study reported the significant increases in CSF T-Tau and CSF and plasma neurofilament light chain levels 1 week after MRgFUS and associated the increases with the T2* hypointensity findings in two patients [20]. In our study, although no group-wise changes in biomarker levels were found, the BBBO volume was significantly correlated with the increased EV levels of GFAP, Tau and pTau-181, 3 days after NgFUS without any abnormalities in MRI. The elevated levels of EV biomarkers indicate the release of proteins to the bloodstream by FUS, consistent with sonobiopsy behavior noted in prior studies [54,55]. As the BBBO volume also correlated with the reduced SUVR increase in the treated brain region, further investigation is warranted to discover the potential of FUS for clearing Alzheimer's disease-related proteins from the brain to the blood stream. The overall increased correlation of BBBO volume with the proteins in serum-derived EVs compared to serum levels alone indicates that EVs may be a more sensitive diagnostic tool for biomarker detection as a result of FUS-mediated BBBO.

Despite the promising findings of the study reported herein, there are several limitations, including a limited number of subjects, a single treatment at a single target location, inconsistency in BBBO volume, and targeting errors. Despite the variability in BBBO volume across the subjects in this trial, employing the updated simulation pipeline with precise transducer positioning holds promise for achieving more consistent and targeted BBBO in future studies. Another limitation of our study is the size of the treated volume, given that Alzheimer's disease impacts broad regions of the brain.^{18,19} To achieve more effective outcomes, our portable NgFUS system can adopt a larger volume treatment approach by utilizing a robotic arm, similar to a pre-clinical study by Leinenga et al [14]. In addition, a subject-specific hologram lens could be employed for a constant focal size across subjects [56]. In future studies, multiple sessions of treatment with more subjects may be performed to evaluate the therapeutic benefits of NgFUS in Alzheimer's disease patients, both with and without a therapeutic agent.

The study presented herein demonstrates the safety and feasibility of transient and non-invasive BBBO in patients with Alzheimer's disease using a portable NgFUS system. The BBBO volume showed linear correlations with the treatment dose (i.e., CCDs), the elevated level of biomarkers in serum-derived EVs, and the asymmetry SUVR changes. This low-cost and reliable technology may facilitate wider adoption of FUS treatment at the point of care for not only Alzheimer's disease but also for several other neurological disorders.

Materials and methods

Study design

This study was a phase 1 clinical trial (NCT04118764) of 6 subjects for evaluating the safety and feasibility of NgFUS-mediated BBBO in patients diagnosed with Alzheimer's disease. The study was approved by the FDA and the Institutional Review Board (IRB) at Columbia University. After providing informed consent, participant eligibility was determined by the neurologist on the study based on the MRI and 18F-florbetapir PET scans, the participant and family interview, and clinical scales including MMSE, geriatric depression scale (GDS), and modified Hachinski ischemia scale (MHIS) (Table S1). Out of the ten subjects screened, 4 subjects were excluded due to low MMSE scores or the need for other medical treatment, and 6 subjects were enrolled in the study. The timeline of the study is presented in Figure 2. All subjects had baseline MRI and PET-CT scans 1–4 months before the treatment. For treatment planning, acoustic simulations were performed to estimate the skull-induced ultrasound attenuation and determine the FUS transducer output for each patient. On the day of treatment, the patient underwent one session of FUS sonication and post-treatment MRI was obtained approximately 2 h after the sonication to assess BBBO and safety. Follow-up MRI scans were acquired 3 days after sonication to confirm BBB reinstatement and safety. Two follow-up PET scans were acquired and a follow-up MMSE was administered on the same day of the 2nd follow-up PET scan. The time line of the individual subject is listed in Table S8.

NgFUS system

We used a single-element 250-kHz FUS transducer (H-231, Sonic Concepts) with a central opening, with guidance achieved using a neuronavigation system (Brainsight; Rogue Research) which was first tested in NHPs [33–35]. The FUS device was cleared by the FDA through an investigational device exemption (IDE G180140) for a first-in-human study at Columbia

University. The -6 dB focal volume of the FUS beam was $6 \times 6 \times 49$ mm³ with an axially-elongated ellipsoidal shape. For cavitation monitoring, either a single-element transducer for subject 1–4 (Figure S10A) or a multi-element imaging array transducer for subject 5 and 6 (Figure S10B) was coaxially inserted in the central opening of the FUS transducer. A research ultrasound system (Vantage 256, Verasonics) was used for cavitation map acquisition. The transducer specifications and experimental parameters are listed in Table S6.

Treatment planning

The target location was selected at an amyloid positive region in the right frontal lobe based on the PET image. The initial FUS trajectory was determined by considering the focal size and the beam incidence angle relative to the skull (Figure 3) for more efficient acoustic energy delivery [39]. Patient-specific numerical simulations were employed for estimating the skull insertion loss of the acoustic pressure using the k-wave toolbox [57,58] and MATLAB (Figure 3B). Heterogeneous maps of the skull density and sound speed were obtained from the CT image acquired during screening (resolution: $0.6 \times 0.6 \times 1$ mm³, Biograph64 mCT, Siemens), where the maximum sound speed and density were assumed to be $c = 4000$ m/s [59] and $\rho = 1850$ kg/m³ [60]. Skull absorption was also modelled based on the CT image with a maximum absorption value of 0.68 dB/cm at the working frequency, assuming a linear frequency dependency [60,61]. A 3-D acoustic pressure map was obtained from the linear acoustic simulation with a grid size of $1 \times 1 \times 1$ mm³ (i.e., 6 points per wavelength) and a time step of 52.5 μ s. The insertion loss α was determined by $\alpha = 1 - P_{\text{skull}}/P_{\text{freefield}}$, where P_{skull} is the maximum pressure within the brain obtained from a simulated acoustic map with skull insertion and $P_{\text{freefield}}$ is the maximum pressure from a simulated map without the skull. More than 35 simulations were performed per subject considering the transducer positioning deviations (i.e., ± 10 mm in distance and $\pm 10^\circ$ in angular deviation). The trajectory was also adjusted to avoid a large deviation of the insertion loss based on the simulation, and was used for FUS treatment as the planned trajectory. The estimated insertion loss along the planned trajectory (Table 2) was used for adjusting the sonication power to deliver the derated *in situ* pressure of 200 kPa.

FUS sonication

The dimensions of the portable FUS system required patients to have partial hair shaving at the right frontal scalp for optimal acoustic coupling between the subject's head and the transducer (Figure S1A). The subject's head was supported with the head and chin rest in a sitting position (Figure 3C), and the anatomical registration to the neuronavigation system was performed based

on the facial landmarks (i.e., eyes, ears, and nose). The chin and head rest was used for subjects 2, 4, 5, and 6. The FUS transducer was positioned with the neuronavigation guidance to place the acoustic focus at the planned target in the right frontal lobe (Figure 3D). The sonication parameters were as follows: derated peak-negative pressure, 200 kPa; mechanical index (MI), 0.4; center frequency, 0.25 MHz; pulse length, 10 ms; pulse repetition frequency, 2 Hz. treatment duration, 2 min. Microbubbles (0.1 mL/kg, Definity, Lantheus) were intravenously injected as a bolus starting at 3 s and finishing at 10–20 s after the start of the sonication, and followed with a saline flush. Approximately 50–75% of the microbubble bolus was introduced into circulation at the time of the flush due to the dead space within the catheter tubing. During the sonication, the frequency spectrum and cavitation dose were monitored ($N=4$), and the cavitation map with ultrasound B-mode image was also employed for the last two subjects ($N=2$) (Figure 3E).

MRI

Baseline (screening), post-FUS (day 0, 2 hr after FUS), and follow-up (day 3) MRI scans were acquired (Figure 2) using a 3-T MRI system (Signa Premier, GE). Safety MR scans were obtained during all three MRI sessions without any MR-contrast agent and included T2-weighted, T2-FLAIR, and SWI with parameters shown in Table S7. T1-weighted images with the gadolinium contrast agent (0.2 mL/kg, Dotarem®) were acquired for the confirmation of BBB opening and closing on day 0 and day 3, respectively. The post-contrast T1-weighted MRI was obtained 15–20 min after the gadolinium injection for increased sensitivity to detect BBBO [62,63]. BBBO on day 0 and closing on day 3 were confirmed by a radiologist. The contrast-enhanced volume was quantified by subtracting the day-3 post-contrast T1-weighted MRI from the day-0 post-contrast T1-weighted MRI and thresholding the subtracted image. The threshold was automatically selected so that the mean intensity within the opening volume is significantly greater than that of the surrounding region with a confidence level of 98% assuming the intensity of the subtracted image follows a Gaussian distribution [35].

Blood Collection and Biomarker Measurement

Blood was collected from patients both prior to BBBO and 3 days post-BBBO to assess blood-based Alzheimer's disease biomarker detection as a result of FUS from both serum and serum-derived EVs. All subjects had blood drawn immediately 1–2 hours prior to the treatment (i.e., baseline) and 3 days after treatment. Serum was isolated after centrifugation of whole blood at 9.4 rcf for 5 min at 4 °C, and serum-derived EVs were isolated using an exosome precipitation solution according to the manufacturer's published protocol (ExoQuick, Systems Biosciences,

Palo Alto, CA). A Luminex multiplex assay was used to quantify proteins in serum and in isolated serum-derived EVs (Luminex Corp., Austin, TX). Single pro-cartaplex kits (ThermoFisher Scientific) were purchased and combined to make a custom multiplex panel for analysis. The biomarker levels of subject 1 were not acquired properly because of mishandling of the blood specimen.

PET/CT

PET/CT scans (CT: no contrast, axial plane, 4 mm section thickness, 4mm section interval) were acquired with a clinical PET scanner (Biograph64-mCT; Siemens) and with ¹⁸F-Florbetapir tracer at 10mCi (Amyvid®; PETNET Solutions). PET/CT scans were acquired 32 to 107 days prior to treatment, 3 to 29 days after treatment as the 1st follow-up time point, and 82 to 164 days after treatment as the 2nd follow-up time point (Table S8). For region-specific amyloid analysis, MRI and PET images were registered to the Montreal Neuroimaging Institute (MNI) space and automatically segmented by tissue types (GM, WM, and perivascular space, as well as into specific brain regions such as the frontal lobe and hemispheres) [64–66]. Image processing software used included Clinica [67], SPM12 [68], Mango [69], and FSL [70]. PET scans of each participant were registered to the MNI space. To investigate changes in A β from a localized region at the site of BBBO to extended regions, three areas were analyzed: BBBO volumes in the GM and WM (SUVR_{BBBO*}), the treated right frontal lobe (SUVR_{FL}), and the treated right hemisphere (SUVR_H). The A β load was quantified from PET scans as SUVR, using the cerebellar gray matter as the reference region [71]. The asymmetry SUVR was measured by dividing the SUVR in the treated region by that in the contralateral untreated region to monitor the relative progression of A β . Changes in SUVR and asymmetry at the 1st and 2nd follow-ups compared to baseline were quantified (Figure 7). SUVR in Centiloid scale was calculated using established methods [72–74], in order to allow standardized comparison with other studies.

Cavitation dose and cavitation map

For cavitation monitoring, a single-element transducer was utilized to obtain CDs for subjects 1–4, while a multi-element imaging array transducer was employed for subjects 5 and 6 to obtain both CDs and cavitation maps (Table S6). The CD was obtained from the 3rd to 6th harmonic/ultraharmonic frequencies. We computed the cavitation dose with harmonic (CD_h), ultraharmonic (CD_u), and broadband frequencies (CD_b) as follows [34]: $CD_h = \sqrt{\sum_{n=3}^6 |P_{h,n}|^2}$,

$CD_u = \sqrt{\sum_{n=3}^6 |P_{u,n}|^2}$, and $CD_b = \sqrt{\sum_{n=3}^6 |\bar{A}_n|^2}$, where $P_{h,n}$ and $P_{u,n}$ are the peak amplitude of the n -th harmonic and the n -th ultraharmonic frequency components, respectively, and \bar{A}_n is the averaged amplitude within the bandwidth of 75 kHz between the n -th harmonic and the n -th ultraharmonic frequencies. For the array transducer, the frequency spectrum was obtained by summing the RF channel data across all the elements and obtaining Fourier transform of the summed signal. The frequency spectrum and the cavitation doses were obtained for every burst. The CD was normalized by the electrical noise power that was obtained using the same processing pipeline but with electrical noise data. The electrical noise data were acquired without FUS transmission. The normalized CD was then converted to the logarithmic scale (i.e. dB) and presented in Figure 5A. The CCD was obtained by summing the normalized CD acquired after the microbubble flush and converting it to the logarithmic scale. We did not subtract the baseline from the CD or CCD due to high fluctuations in the baseline cavitation signals.

The acoustic energy map for each burst was reconstructed in real time from the 64-channel RF data by using the coherence-factor-based passive acoustic mapping implemented on a GPU (RTX A6000, NVIDIA). The final cavitation maps were obtained by averaging the acoustic energy maps for the bursts after the microbubble injection and masking them with the segmented brain volumes obtained from the MR images. More information on passive acoustic mapping implementation can be found in our previous study [35]. The MR image and the quantified BBBO volume were registered with the cavitation map based on the tracked coordinate of the focus by the neuronavigation system and also based on ultrasound B-mode image that delineated the skin and skull; the registered B-mode (or cavitation map) and MRI slice are presented in Figure S11.

Targeting accuracy and precision

The planned target/trajectory of FUS was determined in the planning step before treatment and the treated target/trajectory was sampled during the FUS sonication on the neuronavigation system. Transducer positioning errors were measured by the distance and angle differences between the planned and treated target trajectories to assess the accuracy in the manual placement of the transducer. To evaluate the targeting accuracy of BBBO, the Euclidean distance between the BBBO centroid and the simulated focus was measured for each subject. The subject movement was obtained from the tracked location of the FUS focus which was recorded over time during the sonication by the neuronavigation system.

Post hoc simulation

During the retrospective analysis of data, we found that there was a registration error between CT and MR volumes (1–7 mm). Additionally, there were differences between the treated trajectory for sonication and the planned trajectory for the acoustic simulation before treatment, due to the transducer positioning error. We re-simulated the acoustic pressure fields with the corrected registration and the trajectory. The pressure field (Figure S7), attenuation, and derated peak pressure (Table S5) were obtained with the corrected trajectory and registration. The derated peak pressure \hat{P} was calculated by $\hat{P} = P / (1 - \alpha) \cdot (1 - \hat{\alpha})$ where P is 200 kPa and α and $\hat{\alpha}$ are the original and the newly obtained insertion loss values, respectively.

Statistical Analysis

Statistical analysis was performed in MATLAB (Mathworks). Linear regression analysis was used to evaluate the correlations of the CCDs ($N=4$), biomarker levels ($N=5$), asymmetry SUVR increase, and the simulated maximum pressure ($N=5$) with the contrast-enhanced volume, as well as the correlation between the SUVR asymmetry and CCDs ($N=4$). R-squared and p values were obtained from the regression for the statistical analysis. Pixel-wise correlation between the cavitation map and the BBBO was measured by the AUC of ROC curve and the AUC of PR curve after combining data sets from subject 5 and 6, as described in Bae et al. [35]. MMSE scores of the subjects were compared with those of ADNI subjects by using unpaired t-test. Changes in SUVR and the asymmetry between different time points were analyzed using paired t-test.

Abbreviations

A β	Amyloid beta
AD	Alzheimer's disease
ADNI	Alzheimer's disease neuroimaging initiative
AE	Adverse event
BBB	Blood-brain barrier
BBBO	Blood-brain barrier opening
CCD	Cumulative cavitation dose
CGA-NPI	Caregiver-administered neuropsychiatric inventory
CT	Computed tomography
EV	Extracellular vesicle
FDA	U.S. Food and Drug Administration
FLAIR	Fluid-attenuated inversion recovery
FUS	Focused ultrasound
GM	Gray matter

GPU	Graphics processing unit
IRB	Institutional review board
MMSE	Mini-mental state examination
MRI	Magnetic resonance imaging
MR	Magnetic resonance
MRgFUS	Magnetic resonance-guided focused ultrasound
NHP	Non-human primate
NgFUS	Neuronavigation-guided FUS
PAM	Passive acoustic mapping
PCP	Passive cavitation detection
PET	Positron emission tomography
PR	Precision-recall
ROC	Receiver operating characteristic
SAE	Adverse event
SUVR	Standard uptake value ratio
SUVR _{BBBO*}	Standard uptake value ratio measured within BBBO volume in the gray and white matter
SUVR _{FL}	Standard uptake value ratio measured within the treated frontal lobe
SUVR _H	Standard uptake value ratio measured within the treated hemisphere
SWI	Susceptibility-weighted imaging

Acknowledgments

The authors wish to thank Maria F. Murillo, Fotis Tsitsos, Alexander Berg, Rebecca L. Noel, and Nancy Kwon for support and insightful discussion.

Contributions

ANP, EEK, and LSH initially developed the concept of the study;
SB, KL, ANP, RJ, SJG, OY, DK, LSH, and EEK conducted the FUS treatments;
LSH performed the neurological examinations;
SB processed and analyzed the cavitation, patient motion, and MRI data;
OY, KL, and SJG performed the numerical simulations;
KL and RJ processed and analyzed PET data;
AKS, SB, and AJB processed and analyzed blood biomarker data;
SB, RJ, SJG, KL, AJB, and EEK discussed and reviewed all the data;
KL, DK, ANP, and RJ assisted in patient recruitment;
ANP, KL, RJ, and SB prepared technical and regulatory documentation of the device;
EEK acquired funding and provided resources for the study as a principal investigator;
EEK and LSH supervised the clinical study;
SB wrote the original manuscript and visualized the data;

SB, KL, ANP, RJ, LSH, EEK, AJB, and SJG and edited the manuscript;

All authors reviewed and approved the final manuscript.

Competing interests

Some of the work presented herein is supported by patents optioned to Delsona Therapeutics, Inc. where EEK serves as co-founder and scientific adviser. SB, ANP, RJ, KL, SJG, OY, DK, AKS, AB, and LSH declare no conflict of interest.

References

1. Alzheimer's Association. 2022 Alzheimer's disease facts and figures. *Alzheimer's Dement.* 2022; 18: 1–118.
2. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease. *Journal of Prevention of Alzheimer's Disease.* 2022; 9: 197–210.
3. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. Vol. 388, *The New England Journal of Medicine.* Krause und Pachernegg GmbH; 2023.
4. Mintun M, Solomon P, Sims JR, et al. Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial. In: *Alzheimer's Association International Conference.* Amsterdam; 2023.
5. Daneman R, Prat A. The blood–brain barrier. *Cold Spring Harb Perspect Biol.* 2015; 7: a020412.
6. Wechsler ME, Vela Ramirez JE, Peppas NA. 110th Anniversary: Nanoparticle mediated drug delivery for the treatment of Alzheimer's disease: crossing the blood-brain barrier. *Ind Eng Chem Res.* 2019; 58: 15079–87.
7. Pardridge WM. Treatment of Alzheimer's disease and blood–brain barrier drug delivery. Vol. 13, *Pharmaceuticals.* MDPI AG; 2020.
8. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. *Arch Neurol.* 2012; 69: 1002–10.

9. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. *Vol. 23, Peptides*. 2002.
10. Pandit R, Chen L, Götz J. The blood-brain barrier: Physiology and strategies for drug delivery. *Adv Drug Deliv Rev*. 2020; 165–166: 1–14.
11. McMahon D, O'Reilly MA, Hynynen K. Therapeutic agent delivery across the blood-brain barrier using focused ultrasound. *Annu Rev Biomed Eng*. 2021; 23: 89–113.
12. Chen H, Brayman AA, Kreider W, Bailey MR, Matula TJ. Observations of translation and jetting of ultrasound-activated microbubbles in mesenteric microvessels. *Ultrasound Med Biol*. 2011; 37: 2139–48.
13. Kooiman K, Roovers S, Langeveld SAG, et al. Ultrasound-responsive cavitation nuclei for therapy and drug delivery. *Ultrasound Med Biol*. 2020; 46: 1296–325.
14. Leinenga G, Bodea L, Schröder J, et al. Transcriptional signature in microglia isolated from an Alzheimer's disease mouse model treated with scanning ultrasound. *Bioeng Transl Med*. 2023; 8: e10329.
15. Karakatsani ME, Ji R, Murillo MF, et al. Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients. *Theranostics* [Internet]. 2023; 13: 4102–20. Available at: <https://www.thno.org/v13p4102.htm>
16. Kline-Schoder AR, Noel RL, Phatnani H, Menon V, Konofagou EE. Focused Ultrasound-Mediated Blood–Brain Barrier Opening Best Promotes Neuroimmunomodulation through Brain Macrophage Redistribution. *Neuroglia*. 2023; 4: 141–57.
17. Lipsman N, Meng Y, Bethune AJ, et al. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. *Nat Commun*. 2018; 9: 1–8.
18. Park SH, Baik K, Jeon S, Chang WS, Ye BS, Chang JW. Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study. *Transl Neurodegener*. 2021; 10.
19. Rezai AR, Ranjan M, Haut MW, et al. Focused ultrasound–mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes. *J Neurosurg* [Internet]. 2022; 139: 275–83. Available at: <https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-2022.9.JNS221565/article-10.3171-2022.9.JNS221565.xml>

20. Meng Y, Goubran M, Rabin JS, et al. Blood–brain barrier opening of the default mode network in Alzheimer’s disease with magnetic resonance-guided focused ultrasound. *Brain*. 2023; 146: 865–72.
21. Abrahao A, Meng Y, Llinas M, et al. First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. *Nat Commun* [Internet]. 2019; 10: 1–9. Available at: <http://dx.doi.org/10.1038/s41467-019-12426-9>
22. Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, et al. Blood-brain barrier opening with focused ultrasound in Parkinson’s disease dementia. *Nat Commun*. 2021; 12.
23. Mainprize T, Lipsman N, Huang Y, et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: A clinical safety and feasibility study. *Sci Rep* [Internet]. 2019; 9: 1–7. Available at: <http://dx.doi.org/10.1038/s41598-018-36340-0>
24. Anastasiadis P, Gandhi D, Guo Y, et al. Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. *Proc Natl Acad Sci U S A*. 2021; 118.
25. Meng Y, Reilly RM, Pezo RC, et al. MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. *Sci Transl Med*. 2021; 13: eabj4011.
26. D’Haese PF, Ranjan M, Song A, et al. β -Amyloid plaque reduction in the hippocampus after focused ultrasound-Induced blood–brain barrier opening in Alzheimer’s disease. *Front Hum Neurosci*. 2020; 14.
27. Rezai AR, D’Haese P-F, Finomore V, et al. Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease. *New England Journal of Medicine* [Internet]. 2024; 390: 55–62. Available at: <http://www.nejm.org/doi/10.1056/NEJMoa2308719>
28. Epelbaum S, Burgos N, Canney M, et al. Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer’s disease with an implantable ultrasound device. *Alzheimers Res Ther*. 2022; 14.
29. Jeong H, Song I-U, Chung Y-A, et al. Short-term efficacy of transcranial focused ultrasound to the hippocampus in Alzheimer’s disease: A preliminary study. *J Pers Med* [Internet]. 2022; 12: 250. Available at: <https://www.mdpi.com/2075-4426/12/2/250>

30. Chen K-T, Chai W-Y, Lin C-J, et al. Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors. *Sci Adv.* 2021; 7: eabd0772.
31. Chen K-T, Lin Y-J, Chai W-Y, et al. Neuronavigation-guided focused ultrasound (NaviFUS) for transcranial blood-brain barrier opening in recurrent glioblastoma patients: clinical trial protocol. *Ann Transl Med.* 2020; 8: 673–673.
32. Jeong H, Im JJ, Park JS, et al. A pilot clinical study of low-intensity transcranial focused ultrasound in Alzheimer’s disease. *Ultrasonography.* 2021; 40: 512–9.
33. Pouliopoulos AN, Wu SY, Burgess MT, Karakatsani ME, Kamimura HAS, Konofagou EE. A clinical system for non-invasive blood–brain barrier opening using a neuronavigation-guided single-element focused ultrasound transducer. *Ultrasound Med Biol.* 2020; 46: 73–89.
34. Pouliopoulos AN, Kwon N, Jensen G, et al. Safety evaluation of a clinical focused ultrasound system for neuronavigation guided blood-brain barrier opening in non-human primates. *Sci Rep.* 2021; 11: 15043.
35. Bae S, Liu K, Pouliopoulos AN, Ji R, Konofagou EE. Real-time passive acoustic mapping with enhanced spatial resolution in neuronavigation-guided focused ultrasound for blood-brain barrier opening. *IEEE Trans Biomed Eng.* 2023; 70: 2874–85.
36. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Vol. 342, *Clinica Chimica Acta.* 2004.
37. Huang Y, Meng Y, Pople CB, et al. Cavitation feedback control of focused ultrasound blood-brain barrier opening for drug delivery in patients with Parkinson’s disease. *Pharmaceutics* [Internet]. 2022; 14: 2607. Available at: <https://www.mdpi.com/1999-4923/14/12/2607>
38. Wu SY, Sanchez CS, Samiotaki G, Buch A, Ferrera VP, Konofagou EE. Characterizing focused-ultrasound mediated drug delivery to the heterogeneous primate brain in vivo with acoustic monitoring. *Sci Rep.* 2016; 6.
39. Karakatsani MEM, Samiotaki GM, Downs ME, Ferrera VP, Konofagou EE. Targeting effects on the volume of the focused ultrasound-Induced blood-brain barrier opening in nonhuman primates in vivo. *IEEE Trans Ultrason Ferroelectr Freq Control.* 2017; 64: 798–810.

40. Fry FJ, Kossoff G, Eggleton RC, Dunn F. Threshold ultrasonic dosages for structural changes in the mammalian brain. *J Acoust Soc Am*. 1970; 48: 1413–7.
41. Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, Janigro D. Regional variation in brain capillary density and vascular response to ischemia. *Brain Res*. 2001; 910: 81–93.
42. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: Safety and efficacy evaluation in rhesus macaques. *Cancer Res*. 2012; 72: 3652–63.
43. Zhou H, Liu Y, Long X, et al. Feasibility of ultrasound-induced blood-brain barrier disruption with a single-element transducer under three different frequencies in two non-human primates in vivo: Case report. *J Neurosci Methods*. 2022; 365.
44. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. *Nat Rev Neurol*. 2020; 16: 137–53.
45. Ye D, Chen S, Liu Y, et al. Mechanically manipulating glymphatic transport by ultrasound combined with microbubbles. *Proc Natl Acad Sci U S A*. 2023; 120.
46. Meng Y, Abrahao A, Heyn CC, et al. Glymphatics visualization after focused ultrasound-induced blood–brain barrier opening in humans. *Ann Neurol*. 2019; 86: 975–80.
47. Mehta RI, Carpenter JS, Mehta RI, Haut MW, Ranjan M. Blood-brain barrier opening with MRI-guided focused ultrasound elicits meningeal venous permeability in humans with early Alzheimer disease. *Radiology*. 2021; 298: 645–62.
48. Ji R, Karakatsani ME, Burgess M, Smith M, Murillo MF, Konofagou EE. Cavitation-modulated inflammatory response following focused ultrasound blood-brain barrier opening. *Journal of Controlled Release*. 2021; 337: 458–71.
49. Tung Y-S, Vlachos F, Feshitan JA, Borden MA, Konofagou EE. The mechanism of interaction between focused ultrasound and microbubbles in blood-brain barrier opening in mice. *J Acoust Soc Am*. 2011; 130: 3059–67.
50. Pouliopoulos AN, Kwon N, Jensen G, et al. Safety evaluation of a clinical focused ultrasound system for neuronavigation guided blood-brain barrier opening in non-human primates. *Sci Rep*. 2021; 11: 1–32.

51. Kamimura HAS, Flament J, Valette J, et al. Feedback control of microbubble cavitation for ultrasound-mediated blood–brain barrier disruption in non-human primates under magnetic resonance guidance. *Journal of Cerebral Blood Flow and Metabolism*. 2019; 39: 1191–203.
52. Leinenga G, Götz J. Scanning ultrasound removes amyloid- β and restores memory in an Alzheimer’s disease mouse model. *Sci Transl Med*. 2015; 7: 278ra33.
53. Burgess A, Dubey S, Yeung S, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. *Radiology*. 2014; 273: 736–45.
54. Meng Y, Pople CB, Suppiah S, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. *Neuro Oncol*. 2021; 23: 1789–97.
55. Pacia CP, Yuan J, Yue Y, et al. Focused ultrasound–mediated liquid biopsy in a tauopathy mouse model. *Radiology*. 2023; 307.
56. Jiménez-Gambín S, Jiménez N, Pouliopoulos A, Benlloch JM, Konofagou E, Camarena F. Acoustic holograms for bilateral blood-brain barrier opening in a mouse model. *IEEE Trans Biomed Eng*. 2022; 69: 1359–68.
57. Treeby BE, Cox BT. k-Wave: MATLAB toolbox for the simulation and reconstruction of photoacoustic wave fields. *J Biomed Opt*. 2010; 15: 021314.
58. Treeby BE, Jaros J, Rendell AP, Cox BT. Modeling nonlinear ultrasound propagation in heterogeneous media with power law absorption using a k-space pseudospectral method. *J Acoust Soc Am*. 2012; 131: 4324–36.
59. Marsac L, Chauvet D, la Greca R, et al. Ex vivo optimisation of a heterogeneous speed of sound model of the human skull for non-invasive transcranial focused ultrasound at 1 MHz. *International Journal of Hyperthermia*. 2017; 33: 635–45.
60. Pinton G, Aubry JF, Bossy E, Muller M, Pernot M, Tanter M. Attenuation, scattering, and absorption of ultrasound in the skull bone. *Med Phys*. 2012; 39: 299–307.
61. Bossy E, Padilla F, Peyrin F, Laugier P. Three-dimensional simulation of ultrasound propagation through trabecular bone structures measured by synchrotron microtomography. *Phys Med Biol*. 2005; 50: 5545–56.

62. Israeli D, Tanne D, Daniels D, et al. The application of MRI for depiction of subtle blood brain barrier disruption in stroke. *Int J Biol Sci* [Internet]. 2011; 7: 1–8. Available at: <http://www.biolsci.org>[1](http://www.biolsci.org)<http://www.biolsci.org>
63. Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Vol. 96, *Archives of Toxicology*. Springer Science and Business Media Deutschland GmbH; 2022.
64. Rolls ET, Joliot M, Tzourio-Mazoyer N. Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. *Neuroimage*. 2015; 122: 1–5.
65. Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL. Unbiased average age-appropriate atlases for pediatric studies. *Neuroimage*. 2011; 54: 313–27.
66. Rolls ET, Huang CC, Lin CP, Feng J, Joliot M. Automated anatomical labelling atlas 3. *Neuroimage*. 2020; 206.
67. Routier A, Burgos N, Díaz M, et al. Clinica: An Open-Source Software Platform for Reproducible Clinical Neuroscience Studies. *Front Neuroinform*. 2021; 15.
68. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage*. 2005; 26: 839–51.
69. Lancaster JL, Laird AR, Eickhoff SB, Martinez MJ, Mickle Fox P, Fox PT. Automated regional behavioral analysis for human brain images. *Front Neuroinform*. 2012; 6.
70. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. *Neuroimage* [Internet]. 2012; 62: 782–90. Available at: <https://linkinghub.elsevier.com/retrieve/pii/S1053811911010603>
71. Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal β -amyloid change with 18F-florbetapir PET and standardized uptake value ratios. *Journal of Nuclear Medicine*. 2015; 56: 567–74.
72. Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid- β plaques in patients with prodromal to moderate Alzheimer’s disease: A PET substudy interim analysis. Vol. 11, *Alzheimer’s Research and Therapy*. 2019.

73. Navitsky M, Joshi AD, Kennedy I, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. *Alzheimer's and Dementia*. 2018; 14: 1565–71.
74. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET. *Alzheimer's and Dementia* [Internet]. 2015; 11: 1-15.e4. Available at: <http://dx.doi.org/10.1016/j.jalz.2014.07.003>

Table

Table I. Patient Characteristics

Subject#	1	2	3	4	5	6
Age range	70-74	80-84	65-69	65-69	55-59	70-74
Sex	F	M	F	F	M	F
MMSE	18	20	15	21	24	15
GDS	1	1	2	1	0	0
MHIS	1	0	2	1	0	1

MMSE: Mini-Mental State Examination on the day of screening, GDS: Geriatric Depression Scale on the day of screening, MHIS: Modified Hachinski Ischemia Scale

Table 2. Summary of the treatment.

Subject #	1	2	3	4	5	6
Contrast-enhanced volume (mm ³)	2013	414	0	951	278	1262
Skull-induced attenuation*	0.84	0.72	0.75	0.72	0.7	0.75
Procedure time** (min)	-	38	47	21	36	35
Transducer positioning errors† (mm, °)	-	4.7, 11.2	5.3, 13.0	4.3, 7.0	8.2, 14.5	5.8, 10.5
Subject movements†† (MAD, max) (mm)	-	-	2.3, 9.4	0.5, 1.5	0.25, 1.1	0.28, 0.96
Distance between the BBBO centroid and the simulated focus‡ (mm)	23.2	13.3	-	8.4	5.4	11.3

* Obtained by the acoustic simulation based on the planned target prior to the treatment.

** Time duration for the subject sitting on the treatment chair; including anatomical registration for the neuronavigation, targeting, sonication, and patient release.

† Distance (mm) and angle difference (°) between the planned trajectory and the actual trajectory during the treatment.

†† Subject movement was measured by the mean absolute deviation (MAD) from its centroid and the maximum distance (max) from the initial location.

‡ Distance between the centroid of the BBBO and the estimated focal position in the simulated pressure map

Table 3. Changes in SUVR and asymmetry SUVR at the 1st and 2nd follow-up compared to the baseline (mean±std)

Region	ΔSUVR		ΔAsym.SUVR	
	1st F/U	2nd F/U	1st F/U	2nd F/U
BBBO*	-1.17±5.51, p=.66	5.05±7.20, p=.19	-1.67±5.09, p=.50	-0.68±1.05, p=.22
FL	1.97±5.51, p=.47	6.95±6.51, p=.076	-1.00±1.12, p=.12	-1.47±0.77, p=.013
H	1.43±5.73, p=.61	6.80±5.88, p=.061	-0.64±0.65, p=.092	-0.90±0.26, p=.001

SUVR: standard uptake value ratio, Asym.: asymmetry, BBBO*: blood-brain barrier opening in gray and white matter, FL: frontal lobe, H: hemisphere, F/U: follow-up.

The 1st F/U and 2nd F/Us were 20±9 days and 103±30 days after focused ultrasound treatment, respectively. Mean and standard deviations were calculated from 5 subjects with BBBO.

Figure




Figure 1. Illustration of focused ultrasound (FUS)-induced blood-brain barrier (BBB) opening. Systemically administered microbubbles oscillate under localized FUS and transiently open the BBB for drug delivery or immune-stimulation at the targeted brain tissue. Oscillating microbubbles emit acoustic cavitation signals which can be used for treatment monitoring.




Figure 2. Timeline of the clinical study




Figure 3. Portable NgFUS planning and treatment. (A) Selection of the target and the trajectory of the FUS beam. **(B)** Acoustic pressure map (right) obtained from simulations using CT image (left) for skull insertion loss estimation. **(C)** Subject undergoing the treatment session. The subject's head was supported and fixed by a head and chin rest. The FUS transducer with a coaxial single-element transducer (N=4) or a phased array transducer (N=2) was fixed with the metallic arm during the 2-min treatment. **(D)** Targeting with the real-time feedback of the neuronavigator. **(E)** Real-time cavitation monitoring with the frequency spectrum, cavitation dose, and cavitation energy map (color) with the B-mode image (grayscale) (from top to bottom). With PCD monitoring, only the frequency spectrum and cavitation dose were obtained. With PAM, a cavitation map was obtained as well as the spectrum and dose.




Figure 4. Blood-brain barrier (BBB) opening and closure confirmed by contrast-enhanced T1-weighted MRI. (A) Contrast enhancement indicating BBB opening in T₁-weighted MRI 2 hours after focused ultrasound (FUS) sonication. (B) Lack of contrast enhancement detected on follow-up T₁-weighted MRI confirmed BBB reinstatement on day 3. (C, D) The 3-dimensional (3-D) reconstruction of the FUS beam trajectory (blue line) and segmented contrast-enhanced volume (green) overlaid on the CT skull image (gray) in (C) the sagittal and (D) the coronal view. The maximum pressure point of the focus is denoted as a blue sphere on the blue line. The contrast-enhanced volume was well aligned with the FUS beam trajectory for subjects 4–6. For subjects 1 and 2, the opening was aligned with the trajectory in the sagittal plane (C) but approximately 10 mm off from the trajectory in the coronal plane (D). A video for 360° view of 3-D volumes is available online as Supplementary Movie 1.




Figure 5. Real-time cavitation monitoring during focused ultrasound (FUS) treatment. (A) Harmonic, ultraharmonic, broadband cavitation doses (CDs) during the sonication. The CDs of subjects 1, 2, and 4 increased after the microbubble injection and flush and were sustained until the end of sonication. In contrast, the CDs of subject 3, who did not exhibit successful BBBO, were unstable and exhibited a sudden reduction at $t = 90$ s. The gray arrow indicates the moment of a sudden subject movement detected (Supplementary Fig. 4A). **(B)** Spectrograms displayed during the sonication showed the increased cavitation signal in subjects 1, 2, and 4. Vertical dotted and dashed lines in (A) and (B) indicate the time of the microbubble bolus injection and the subsequent saline flush, respectively. The amplitude in (B) was normalized by the baseline broadband cavitation dose to better represent harmonic and ultraharmonic components. **(C)** Positive correlation between the BBBO volume (i.e., contrast-enhanced volume) and the cumulative CDs (CCDs) over time. **(D)** Cavitation map (color), which presents the distribution of acoustic cavitation energy, is overlaid on the corresponding ultrasound B-mode image (gray) that shows the scalp and the skull profiles. The brain region obtained from the registered MRI is marked as a blue line. **(E)** Projected contrast-enhanced volume (color) overlaid on the MRI slice that is registered to the cavitation map/B-mode image in (D). White dashed lines and ellipsoids in (D) and (E) show the focus of the FUS beam.




Figure 6. Correlation of blood-brain barrier opening (BBBO) volume and blood biomarker levels on day 3 after neuronavigation-guided FUS (NgFUS). A larger BBBO volume is associated with an increased log-fold change in biomarker concentration three days after treatment for **(A)** S100 β in serum, **(B)** A β 42, **(C)** A β 42/A β 40, **(D)** GFAP, **(E)** Tau, and, **(F)** pT181 in extracellular vesicles.




Figure 7. Percent changes in the standard uptake value ratio (SUVR) and asymmetry SUVR of ^{18}F -Florbetapir and the correlation between the change in the asymmetry SUVR and the cumulative cavitation dose (CCD). (A–C) Percent changes in SUVR within the blood-brain barrier opening (BBBO) volume in the gray and white matter ($\Delta\text{SUVR}_{\text{BBBO}^*}$), the right frontal lobe ($\Delta\text{SUVR}_{\text{FL}}$), and the right hemisphere ($\Delta\text{SUVR}_{\text{H}}$), at the 1st and the 2nd follow-ups compared to the baseline. (D–F) Percent changes in asymmetry SUVR (Asym.SUVR) within the BBBO volume in the gray and white matter ($\Delta\text{Asym.SUVR}_{\text{BBBO}^*}$), the right frontal lobe ($\Delta\text{Asym.SUVR}_{\text{FL}}$), and the right hemisphere ($\Delta\text{Asym.SUVR}_{\text{H}}$) compared to the baseline. Significant reduction in asymmetry values were found when measured within the (E) frontal lobe and (F) hemisphere regions. * $p < 0.05$, ** $p < 0.01$. (G) Linear correlation between the $\Delta\text{Asym.SUVR}_{\text{BBBO}^*}$ and the BBBO volume in the gray and white matter. (H) Linear correlations of $\Delta\text{Asym.SUVR}_{\text{BBBO}^*}$ with harmonic, ultraharmonic, broadband CCDs.